Cited by 4,914Parkinson's Disease Mechanisms and TreatmentsForensic Toxicology and Drug AnalysisNuclear Receptors and Signaling

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

Langston, J. William, Ballard, Philip, Tetrud, James W., Irwin, Ian·1983·Science

Abstract

Four persons developed marked parkinsonism after using an illicit drug intravenously. Analysis of the substance injected by two of these patients revealed primarily 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) with trace amounts of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP). On the basis of the striking parkinsonian features observed in our patients, and additional pathological data from one previously reported case, it is proposed that this chemical selectively damages cells in the substantia nigra.

Integrity signals

Registry

Crossref · 10.1126/science.6823561

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MPTP causes parkinsonism by selective inhibition of mitochondrial complex-I of the electron transport chain.

    “The most compelling evidence of mitochondrial dysfunction in PD comes from the accidental discovery of the synthetic meperidine analogue 1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine (MPTP), which causes parkinsonism by selective inhibition of mitochondrial complex-I of the electron transport chain4, 5.”

    From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [4]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I.
Venue
Science
Published
1983-02-25
Volume
219
Issue
4587
Pages
979-980
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W1969800514
Cited by
4,914
References
3
Citations by year
2026: 54 · 2025: 73 · 2024: 88 · 2023: 105 · 2022: 120 · 2021: 126 · 2020: 156 · 2019: 116 · 2018: 135 · 2017: 149 · 2016: 104 · 2015: 121 · 2014: 131 · 2013: 146 · 2012: 151
FWCI
122.07
Type
journal article
Language
en
Open access
closed
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords
parkinsonism, MPTP, intravenous drug use, substantia nigra, neurotoxicity, Parkinson's disease
MeSH terms
Adult, Female, Humans, Male, Meperidine, Opioid-Related Disorders, Parkinson Disease, Secondary, Substantia Nigra

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review